10-Year Outcome of Complete or Infarct-Artery-Only Revascularization in STEMI with Multivessel Disease (DANAMI-3-PRIMULTI) [0.03%]
STEMI并多支病变患者行完全血运重建或罪犯血管血运重建的长期预后（DANAMI-3-PRIMULTI）
Jasmine M Marquard,Rasmus P Beske,Henning Kelbæk et al.
Jasmine M Marquard et al.
Background: The long-term outcomes of complete revascularization in ST-segment elevation myocardial infarction (STEMI) and multivessel disease is unknown. ...
Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients without ASCVD: The VICTORION-Mono Randomized Clinical Trial [0.03%]
inclisiran单药治疗非动脉粥样硬化性心血管疾病患者的安全性和调脂疗效：VICTORION-MONO随机临床试验
Pam R Taub,Alexis Gutierrez,Donavon Wewers et al.
Pam R Taub et al.
Background: Inclisiran administration twice-yearly (after initial and 3-month doses) effectively reduces low-density lipoprotein cholesterol (LDL-C) in patients on maximally tolerated statins with atherosclerotic cardiova...
Transthyretin Gene Silencing in Amyloid Transthyretin Cardiomyopathy: A Novel Treatment Delivers New Dilemmas [0.03%]
转甲状腺素蛋白基因沉默与遗传性转甲状腺素蛋白淀粉样变性心肌病：新疗法带来新难题
Amrut V Ambardekar,Sarah A M Cuddy
Amrut V Ambardekar
Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B [0.03%]
Vutrisiran改善ATTR淀粉样变性心肌病患者的生存率并减少心血管事件：HELIOS-B研究
Ronald M Witteles,Pablo Garcia-Pavia,Thibaud Damy et al.
Ronald M Witteles et al.
Background: Patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) have high mortality and morbidity. Vutrisiran, a subcutaneous RNA interference therapeutic, reduced the composite of all-cause mortality (A...
Homozygous Familial Hypercholesterolemia Is a Life-Limiting Condition: Medical Life-Trajectories in the Post-2010 Era [0.03%]
纯合子型家族性高胆固醇血症是一种致死性疾病：2010年后医疗生存轨迹分析
Janneke W C M Mulder,M Doortje Reijman,D Meeike Kusters et al.
Janneke W C M Mulder et al.
Ask T Nordestgaard,Anne Tybjærg-Hansen,Hank Mansbach et al.
Ask T Nordestgaard et al.
Lipoprotein lipase regulates triglyceride hydrolysis and contributes to cellular uptake of triglyceride-rich lipoprotein remnants. Multiple pathways modulate lipoprotein lipase activity, which has prompted interest in the development of dru...
Effects of Tirzepatide in Type 2 Diabetes: Individual Variation and Relationship to Cardiometabolic Outcomes [0.03%]
tirzepatide对2型糖尿病个体差异及心代谢结局的影响
Arya Aminorroaya,Evangelos K Oikonomou,Dhruva Biswas et al.
Arya Aminorroaya et al.
Background: Tirzepatide-a dual GIP/GLP-1 receptor agonist-exerts pleiotropic effects on cardiometabolic health. Objectives: The authors...
Plozasiran and Apolipoprotein C-III Inhibition: Lipoprotein Particle Insights and Cardiovascular Implications [0.03%]
靶向血管紧张素Ⅱ受体的降压药物与冠心病风险：FAVORITE研究的事后分析
Gregory G Schwartz,Christa M Cobbaert
Gregory G Schwartz
Angiopoietin-Like Protein 3 Inhibition: A Key to Silencing Residual Lipid Risk? [0.03%]
血管生成素样蛋白3抑制：降低残余脂质风险的关键？
Erik S G Stroes,Bram M Weijs,Maxim E Annink
Erik S G Stroes
Harlan M Krumholz
Harlan M Krumholz